ILLINOIS
Veterinary Teaching Hospital
COLLEGE OF VETERINARY MEDICINE

Funded Study: Treatment of Canine Lymphoma

University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory

Study Title: Study to Determine the Efficacy and Safety of Alternating Rabacfosadine and Doxorubicin Treatments Against Multicentric Lymphoma in Previously Untreated Dogs

Purpose of Study: Non-Hodgkin lymphoma (NHL) or lymphosarcoma (LSA), the most common hematopoietic tumor of dogs, is an aggressive disease. While the majority of dogs will respond to cytotoxic chemotherapy utilizing a standard multi-agent (e.g. CHOP-based) approach, greater than 95% of dogs will relapse with chemotherapy-refractory disease. The median survival time is approximately 1 year from diagnosis.

The objective of this study is to evaluate the safety and efficacy of rabacfosadine for injection (formerly VDC-1101/GS-9219) and doxorubicin in dogs with previously untreated spontaneous multicentric lymphoma, when rabacfosadine for injection and doxorubicin are alternately administered every 21 days.

Inclusion Criteria:

- Histologic or cytologic diagnosis confirmatory of lymphoma
- Must have peripherally accessible and measurable disease
- Therapy naïve, including the use of corticosteroids
- Adequate organ function indicated by standard laboratory tests
- Documentation of immunophenotype
- West Highland White Terriers are ineligible

Eligibility Diagnostics:
Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed in their dog:

1) Diagnosis of lymphoma with histopathology or cytology, if not already documented
2) Screening blood work and urinalysis, if not performed within 7 days
3) Immunophenotype of lymphoma, if not already documented
4) Thoracic radiographs will be strongly recommended

Treatment:
Dogs will receive alternating dosages of doxorubicin and rabacfosadine once every 3 weeks for a total of 6 cumulative treatments. Each dog will have routine blood work, urinalysis, lymph node measurements, and chest radiographs at defined scheduled reevaluations.

Compensation:
Pet owners are financially responsible for all diagnostics such as blood work and cytology required for their pets to be deemed eligible for study recruitment. After patients have been deemed eligible, this is a partially funded trial, and dogs will receive rabacfosadine free of cost.

Contact Information: Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information.
Referring veterinarian and client calls are welcome.